The Antiviral Efficacy and Safety of Azvudine in Hospitalized SARS‐CoV‐2 Infected Patients with Liver Diseases Based on a Multicenter, Retrospective Cohort Study

Documenti analoghi

• Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study
  di: Junyi Sun, et al.
  Pubblicazione: (2025)
• Cover Picture: Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study (View 2/2025)
  di: Junyi Sun, et al.
  Pubblicazione: (2025)
• Effectiveness and Safety of Oral Azvudine for Elderly Hospitalized Patients With COVID‐19: A Multicenter, Retrospective, Real‐World Study
  di: Ranran Sun, et al.
  Pubblicazione: (2025)
• The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study
  di: Bo Yu, et al.
  Pubblicazione: (2025)
• Alterations of the oral microbiome in patients reinfected with SARS‐CoV‐2 omicron variants
  di: Benchen Rao, et al.
  Pubblicazione: (2025)